HMO Cancer Research Network (CRN) Research Resource Concept

Rachel Ballard-Barbash, MD, MPH
Martin Brown, PhD (CRN Program Director)

NCI Board of Scientific Advisors
June 20, 2011
Presentation Outline

• Need for National Research Resource
• Unique Qualities of CRN to Serve as National Resource
• Proposed Areas of Scientific Excellence
• Components of New RFA / Budget
• Metrics of Success
• Other NIH HMORN initiatives
Need for National Research Resource within Health Care Delivery Systems

- Rapid expansion in complexity and cost of cancer diagnostic technologies and treatment
  - Lack of research on the interactions among treatments or outcomes of expanded diagnosis
- No other initiative can support diverse multilevel research designs to examine these issues within context of clinical care
- Innovations in EMRs and patient portals have changed landscape of research within the context of care delivery
CRN: Unique Strengths and Opportunities

- Size, scope, and network of research quality data from EHR/VDW
  - Millions of patients with longitudinal clinical care data

- Capacity to evaluate natural experiments that influence cancer care and determine if results from research in controlled settings lead to same outcomes in clinical practice
  - E.g.: Post-market evaluation of drug outcomes or extent of variation in care for recommended therapies

- Provides unique platform for conduct CER as drugs and diagnostic procedures multiple and evolve
  - E.g. Examine drug interactions in complex patients treated with multiple drugs, clinical trials focused on practice questions, and longitudinal studies on health outcomes

- Enables research on how to best provide high quality, targeted care while reducing inefficiencies and cost
Chemotherapy Induced Heart Failure is High in Clinical Practice Compared to RCTs

- Based on 13,321 women aged 22-102 and diagnosed with breast cancer from 1999-2007
- Rate in RCTs is 2-4%

*Adjusted for: health plan, age, Charlson score, summary stage, year of diagnosis, radiation treatment

Bowles EA et al. In preparation for publication
Radiation Exposure has Increased Dramatically: Data from 5 CRN HMOs

Mean Annual Effective Dose and Dose Incurred by the Highest 1% and 10% of Patients

For each patient in each year, radiation from all imaging examinations was summed.

Smith-Bindman R et al. In preparation for publication.
CRN consists of 14 research centers (U19), affiliated with HMOs that provide care for 11 million individuals.
Nature of CRN Data

• Patient-specific clinical care data documented in context of regular practice are transformed into standardized, high quality data that can be used for cancer research.

• Retention rate for cancer survivors is nearly 85% at five years post-diagnosis.

• Longitudinal clinical care data are unique to the CRN.

• CRN is well suited for studies of cancer quality of care, survivorship, and long-term outcomes.

• Can address issues in patients with rare cancer or complex medical conditions that cannot be well studied with existing clinical trial systems.
Virtual Data Warehouse (VDW)

The VDW is populated by automated data from the following sources:

- Tumor registry
- Enrollment
- Demographics
- Geocoding
- Utilization
- Laboratory
- Pharmacy
- Chemotherapy
- Radiology
- Pathology

- ~11,000,000 total enrollees
- ~100,000 incident cancers/year
- ~69,000,000 Rx fills/year
- 505 clinic sites
- 8 affiliations with cancer centers
Cancer Counter Enables Rapid Assessment of Power for Specific Research Questions

Cancer Counter — Create 1-way frequency table
Pick a 1-way cross-tab which will display for the frequencies of the special dataset that you selected and that were counted on the previous case selection page.

<table>
<thead>
<tr>
<th>CRN Plan</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRN Plan 1</td>
<td>375</td>
</tr>
<tr>
<td>CRN Plan 2</td>
<td>259</td>
</tr>
<tr>
<td>CRN Plan 3</td>
<td>1,995</td>
</tr>
<tr>
<td>CRN Plan 4</td>
<td>1,435</td>
</tr>
<tr>
<td>CRN Plan 5</td>
<td>123</td>
</tr>
<tr>
<td>CRN Plan 6</td>
<td>211</td>
</tr>
<tr>
<td>CRN Plan 8</td>
<td>34</td>
</tr>
<tr>
<td>CRN Plan 10</td>
<td>249</td>
</tr>
<tr>
<td>CRN Plan 11</td>
<td>74</td>
</tr>
</tbody>
</table>

Your selected dataset Primary Tumor Count: 4,765

CRN Ovarian Cancer Counts by Plan, 1995-2002, n = 4,765
Recommendations from External Evaluation

D. Ransohoff, K. Kerlikowske, D. Schrag, T. Tosteson

“CRN provides unique data and has capacity to serve as a national resource that should be preserved and strengthened”

• Support infrastructure and collaboration rather than specific scientific projects

• Develop and maximize mechanisms and interfaces to facilitate collaboration of external researchers with CRN

• Formulate strongest scientific questions by cultivating expertise from CRN and external investigators

• Develop governance structure to target areas of scientific excellence
Key Areas of Scientific Excellence

- Health Care Delivery Research
- Molecular & Genomic Technologies
- Risk Stratification
- CRN Sites
- Extramural Research Community
- Medical Decision Making
- Emerging Tech
- Cancer Survivorship
Key Areas of Scientific Excellence

• **Use of molecular and genomic technologies in community practice**
  - Which patient groups experience improved outcomes from treated tailored on clinical characteristics and molecular? (i.e. Do colorectal cancer patients receive KRAS/BRAF testing, and does it alter care and improve outcomes?)

• **Health care delivery research**, including multi-level systems and comparative effectiveness research of cancer services
  - Can EMR-based outreach be combined with pharmacy data to identify women non-adherent to adjuvant hormonal treatment (i.e., tamoxifen, raloxifene) and interventions be developed to improve treatment adherence and outcomes?
Key Areas of Scientific Excellence

• Quantification of risk stratification though large-scale epidemiologic studies that utilize data on molecular, biologic, behavioral, lifestyle, pharmacologic, radiologic, and other risk (and protective) factors
  – What is the long-term cancer risk/benefit associated with common drugs, such as NSAIDS or statins, or cumulative radiation exposure from common imaging studies?

• Increased understanding of medical decision making, and development / evaluation of tools to enhance physician-patient cancer communication and improve care quality
  – Can physician and patient web portals, informed by data from EMRs, improve continuity of care for cancer patients to enhance treatment decision making and increase adherence to guideline-consistent care?
Key Areas of Scientific Excellence

- **Cancer survivorship**, including long-term consequences of cancer treatment, surveillance, supportive care, care coordination, recurrence, quality of life, and family burden
  - Which breast cancer patients treated with anthracyclines and/or trastuzumab are at greater risk of cardiotoxicity than similar patients treated with no chemotherapy?

- Validation, dissemination, and implementation research on **emerging technologies** including risk prediction, diagnostic and prognostic, and informatics / communications technologies
  - Is it possible to determine clinical and molecular markers that reliably predict low risk of breast cancer recurrence in women diagnosed with ductal carcinoma in situ?
Components of New Research Resource RFA

Total budget = $4.0M per year for 5 years
Components of Research Resources Coordinating Center

- Coordinate/Manage Research Resources
- Provide Research Resources for Collaborations
- Manage Administration of Developmental Pilot Projects
- Manage Administration of Areas of Scientific Excellence
CRN Has Demonstrated Capacity to Serve as a National Resource

• Increased use of the HMORN for national research
  – Recognized by AHRQ, FDA, NIH OD, and other NIH institutes

• Successful competition for competitive funding
  – Increase in number of funded grants using CRN as a resource since 2006
  – 50% of these collaborative grants awarded to PIs outside the CRN

• Growth in rate of scientific publications
  – At least 210 publications in peer-reviewed scientific journals; over 100 published in last 4 years

• Professional development of junior investigators
  – Over 40 investigators have interfaced with the CRN in their training; CRN Scholars Program was implemented in 2007
Growth in Funded* Research Projects Using the CRN, 1999-Present

*Includes NCI-funded grants and contracts as well as projects funded by AHRQ, CDC, DoD, ACS, IOM, and NHGRI that used the CRN; http://crn.cancer.gov/projects/projects.php
Growth in CRN Publication Rate, 1999-Present

![Bar chart showing the growth in CRN publication rate from 1999 to the present. The chart indicates a significant increase in the number of publications, particularly from 2005 to 2006, with a notable rise in the 2009-Present period. The chart distinguishes between non-core and core U19 publications.]
What Will Be Lost if CRN U24 RFA is Not Funded?

• Cancer-directed resource within community practice for CER and other PCORI-related research

• Potential for rapidly evaluating the effects of new cancer discoveries within clinical practice

• Further enhancement and development of VDW with data elements in cancer domains
  – Examples: chemotherapy agents; radiation; prognostic biomarkers; biospecimen linkage; recurrence; adverse events; screening; risk factors; co-morbidities

• Proactive facilitation of ongoing engagement with Cancer Centers and cooperative groups

• Engagement of external researchers in developing cancer specific areas of scientific excellence and related collaborative research
Issues Addressed with Change to U24

- Develop a focused and limited set of areas of scientific excellence with membership from CRN sites that can contribute substantively. Incorporate extramural researchers as key members of these teams.
  - Issue: Lack of focused scientific agenda, especially in cancer treatment related research

- Mandate specific performance criteria in RFA that will be evaluated annually; failure to meet requirements will result in improvement plans, adjustments to funding, and other relevant actions.
  - Issue: Variable capacity across sites to engage in meaningful research

- Formalize relationships between CRN oncologists, other CRN researchers, and NCI cooperative groups; enhance existing relationships between CRN sites and cancer centers; increase visibility of CRN to the entire extramural research community
  - Issue: Limited targeted engagement of external investigators with expertise in cancer
Issues Addressed with Change to U24

• Provide dedicated resources to “navigate” inception and development of new collaborative research projects with external collaborators.
  – Issue: Less than optimal process for conceptualizing and implementing collaborative research projects

• Engage more cancer expertise and more closely monitor CRN site and project performance. Based on maturation of infrastructure, increased recent grant funding, and engagement of more clinical experts, the increase in research publications is expected to continue and improve further.
  – Issue: Less than optimal utilization of the CRN resource in terms of timely scientific publication and dissemination of research results into practice and policy
More Rapid Engagement of Extramural Investigators

• Trans-NCI Program Announcement
  – Approach for highlighting unique areas of scientific excellence and key questions within those areas

• Competitive funding mechanism
  – Could bring specialized expertise and technical resources into collaboration with CRN
  – Enhance more timely and efficient examination of selected research priorities
  – Supplement existing NCI initiatives, such as cancer centers, cooperative groups and other grant mechanisms
Metrics of Success

• Use of CRN as a “real world” population test-bed for cancer care innovations

• Research capacity
  • Durable, robust, validated resource that can be re-used for multiple projects across multiple domains
  • Ability to rapidly establish retrospective cohorts and prospective accrual to multi-level intervention studies or pragmatic trials

• Success in developing focused scientific areas of excellence

• Increased scientific research productivity (e.g. grant funded research projects) with outcomes disseminated into practice

• Others: Collaborative success; Develop future research leaders
Other NIH HMORN Initiatives

• HMO Research Network Collaboratory (NIH Common Fund)
  – Will not address diseases covered by other larger NIH ICs (cancer, heart disease)
  – Designed to address research questions for less common diseases (smaller NIH institutes) or research needs common to many diseases

• Larger disease specific IC efforts are continuing
  – Cardiovascular Research Network (NHLBI)
  – Mental Health Data Resource (NIMH)

• Synergy and coordination with NCI initiatives and other initiatives across HHS
Components of New Research Resource RFA

- CRN Sites
- Areas of Scientific Excellence
- Research Resources Coordinating Center
- Developmental Pilot Projects
- Collaboration Enhancement
- Extramural Research Community
- Training & Professional Development
- Areas of Scientific Excellence

Diagram showing the integration of various components into the new research resource RFA.